A Phase 1 interventional study of PF-06741086 in Severe Hemophilia, sponsored by Pfizer. Completed at 1 site in China. Open to male participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2023-07-07.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Hemophilia A by Pfizer — 6 open to participants now, 9 under way, 6 of them phase 3. Hemophilia A · Pfizer.
Among the 47 studies in Hemophilia A by Pfizer, this one is the 29th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2021, is one of 5 in phase 1, and was the 39th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →6 of the 47 studies in Hemophilia A by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 12–74
Pfizer · Sites in United States, India, Turkey
Ages 12–74 · Men only
Pfizer · Sites in United States, Australia, Canada and 10 more countries
Ages 18+ · Men only
Pfizer · Sites in United States, Argentina, Australia and 20 more countries
Ages 1–17 · Men only
Pfizer · Sites in United States, Argentina, Australia and 21 more countries
Ages 1–74 · Men only
By country, each count listing its studies:
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 74 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 3 started in 2021.
This study's enrollment of 6 is below the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 34 across the 32 interventional studies, 52 across the 13 observational. Of the 34 that completed or were terminated, 25 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Hemophilia A by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06703606PfizerA Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A. | 2027-05-05 |
Add it to your calendar (.ics) → With an account.
Among the 47 studies in Hemophilia A by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 1 study will be a single-arm, open-label, non-randomized, non-controlled investigation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06741086 in Chinese adult participants with severe hemophilia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants without inhibitor must also meet the following criteria:
Participants with Inhibitor must also meet the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF-06741086 300mg subcutaneous(SC)
Biological: PF-06741086
single dose SC injection of 300 mg PF-06741086
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with study treatment. TEAEs=AEs that started during the effective duration of treatment regardless of whether a similar event existed at baseline. Grades of AEs were defined by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1=asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated;Grade 2=minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activity of daily living (ADL);Grade 3=severe or medically significant but not immediately life-threatening, hospitalization of prolongation of hospitalization indicated; disabling limiting self-care ADL;Grade 4=events with life-threatening consequences, urgent intervention indicated;Grade 5= death related to AE.Treatment-related TEAEs were determined by investigator.
Time frame: Day 1 to Day 42
Number of Participants With Serious Adverse Events (SAEs)
An SAE was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect. Treatment-related SAEs were determined by the investigator.
Time frame: Day 1 to Day 42
Number of Participants With Maximum Grade 3 or 4 or 5 TEAEs
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with study treatment. TEAEs=AEs that started during the effective duration of treatment regardless of whether a similar event existed in the baseline period. Grades of AEs were defined by NCI CTCAE version 5.0. Grade 1=asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2=minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activity of daily living (ADL); Grade 3=severe or medically significant but not immediately life-threatening, hospitalization of prolongation of hospitalization indicated; disabling limiting self-care ADL; Grade 4=events with life-threatening consequences, urgent intervention indicated; Grade 5= death related to AE. Treatment-related TEAEs were determined by the investigator.
Time frame: Day 1 to Day 42
Number of Participants With TEAEs Leading to Permanent or Temporary Discontinuation From Study
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with study treatment. TEAEs=AEs that started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period. Grades of AEs were defined by NCI CTCAE version 5.0. Grade 1=asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2=minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activity of daily living (ADL); Grade 3=severe or medically significant but not immediately life-threatening, hospitalization of prolongation of hospitalization indicated; disabling limiting self-care ADL; Grade 4=events with life-threatening consequences, urgent intervention indicated; Grade 5= death related to AE. Treatment-related TEAEs were determined by the investigator.
Time frame: Day 1 to Day 42
Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality
Laboratory assessments included chemistry, hematology, Prothrombin Time/International Normalized Ratio (PT/INR), Activated Partial Thromboplastin Time (APTT), urinalysis, fibrinogen, Antithrombin III (ATIII) activity, and Cardiac Troponin I (cTnI). Laboratory test abnormalities reported by at least 1 participant are reported in this outcome measure. ULN = upper limit of normal.
Time frame: Day 1 to Day 28
Mean Absolute Value of Prothrombin Time (PT) / International Normalized Ratio (INR)
PT is one of the laboratory tests to evaluate the ability of blood clotting. The INR is derived from PT which is calculated as a ratio of a participant's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the World Health Organization (WHO) using the following formula: INR = Participant PT / Control PT. Blood samples were obtained to evaluate PT/INR.
Time frame: Day 1, Day 2, Day 7, Day 14, Day 21, Day 28
Change From Baseline in PT/INR at Days 2, 7, 14, 21 and 28
PT is one of the laboratory tests to evaluate the ability of blood clotting. The INR is derived from PT which is calculated as a ratio of a participant's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the WHO using the following formula: INR = Participant PT / Control PT. Blood samples were obtained to evaluate PT/INR.
Time frame: Baseline (Day 1), Day 2, Day 7, Day 14, Day 21, Day 28
Mean Absolute Value of Activated Partial Thromboplastin Time (APTT)
The APTT is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood samples were obtained to evaluate APTT.
Time frame: Day 1, Day 2, Day 7, Day 14, Day 21, Day 28
Change From Baseline in APTT at Days 2, 7, 14, 21 and 28
The APTT is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood samples were obtained to evaluate APTT.
Time frame: Baseline (Day 1), Day 2, Day 7, Day 14, Day 21, Day 28
Mean Absolute Value of Fibrinogen
Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.
Time frame: Day 1, Day 2, Day 7, Day 14, Day 21, Day 28
Change From Baseline in Fibrinogen at Days 2, 7, 14, 21 and 28
Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.
Time frame: Baseline (Day 1), Day 2, Day 7, Day 14, Day 21, Day 28
Mean Absolute Value of Antithrombin III (ATIII)
ATIII is a nonvitamin K-dependent protease that inhibits coagulation by lysing thrombin and factor Xa. The antithrombin activity test measures how well the protein inhibits thrombin, with a reference range of 75% - 125%. Blood samples were obtained to evaluate ATIII activity.
Time frame: Day 1, Day 2, Day 7, Day 14, Day 21, Day 28
Change From Baseline in ATIII at Days 2, 7, 14, 21 and 28
ATIII is a nonvitamin K-dependent protease that inhibits coagulation by lysing thrombin and factor Xa. The antithrombin activity test measures how well the protein inhibits thrombin, with a reference range of 75% - 125%. Blood samples were obtained to evaluate ATIII activity.
Time frame: Baseline (Day 1), Day 2, Day 7, Day 14, Day 21, Day 28
Mean Absolute Value of Cardiac Troponin I (cTnI)
cTnI is one of the cardiac regulatory proteins that control the calcium mediated interaction between actin and myosin, and is considered a specific marker for cardiac damage. Blood samples were obtained to evaluate the amount of cTnI.
Time frame: Day 1, Day 2, Day 4
Change From Baseline in cTnI at Days 2 and 4
cTnI is one of the cardiac regulatory proteins that control the calcium mediated interaction between actin and myosin, and is considered a specific marker for cardiac damage. Blood samples were obtained to evaluate the amount of cTnI.
Time frame: Baseline (Day 1), Day 2, Day 4
Number of Participants With Vital Signs Data Meeting Categorical Criteria of Potential Clinical Concern
Vital signs measurements included blood pressure (BP), pulse rate, respiratory rate and oral temperature. Categorical classes for vital signs of potential clinical concern included: (1) systolic BP - minimum (min) value \<90 mmHg, maximum (max) decrease/increase from baseline \>=30 mmHg; (2) diastolic BP - min value \<50 mmHg, max decrease/increase from baseline \>=20 mmHg; (3) supine pulse rate - min \<40 beat per minute (bpm) or max \>120 bpm; (4) standing pulse rate - min \<40 bpm or max \>140 bpm; (5) oral temperature \> 38.5 celsius degree (°C). BPs were measured in a supine position so standing BPs were not evaluated and not reported.
Time frame: Day 1 to Day 28
Change From Baseline in Supine Systolic BP at Days 1, 2, 3, 4, 7, 14, 21 and 28
BPs were assessed in a supine position with a completely automated device. Categorical classes for supine systolic BP of potential clinical concern included min value \<90 mmHg, max decrease/increase from baseline \>=30 mmHg.
Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Change From Baseline in Diastolic Systolic BP at Days 1, 2, 3, 4, 7, 14, 21 and 28
BPs were assessed in a supine position with a completely automated device. Categorical classes for supine diastolic BP of potential clinical concern included min value \<50 mmHg, max decrease/increase from baseline \>=20 mmHg.
Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Change From Baseline in Supine Pulse Rate at Days 1, 2, 3, 4, 7, 14, 21 and 28
Pulse rates were assessed in a supine position with a completely automated device. Categorical classes for supine pulse rate of potential clinical concern included min value \<40 bpm or max value \>120 bpm.
Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Change From Baseline in Oral Temperature at Days 1, 2, 3, 4, 7, 14, 21 and 28
No eating, drinking, or smoking was allowed for 15 minutes prior to the measurement of oral temperature. The criterion for oral temperature of potential clinical concern was oral temperature \> 38.5°C.
Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Change From Baseline in Respiratory Rate at Days 1, 2, 3, 4, 7, 14, 21 and 28
Respiratory rate measurement was preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Respiratory rate was measured in terms of "breaths per minute", and was measured by observing and counting the respirations of the participant for 30 seconds and multiplied by 2.
Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Number of Participants With Electrocardiogram (ECG) Data Meeting Categorical Criteria of Potential Clinical Concern
Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated heart rate and measured PR, QRS and QT intervals. If a single time point ECG was abnormal, a triplicate ECG was required and obtained approximately 2-4 minutes apart; the average of triplicate ECG measurements collected at pre-dose Day 1 served as each participant's baseline value. Categorical classes for ECG data of potential clinical concern included: (1) QTcF - 450 millisecond (msec)≤ max value \<480 msec, 480 msec ≤ max value \<500 msec, max value ≥500 msec; 30 msec ≤ QTcF max increase from baseline \<60 msec; max increase from baseline ≥60 msec; (2) PR interval - max value ≥300 msec, baseline value\>200 and max increase from baseline ≥25%, baseline value ≤200 and max increase from baseline ≥50%; (3) QRS interval - max value ≥140 msec, increase from baseline ≥50%.
Time frame: Day 1 to Day 28
Change From Baseline in ECG Mean Heart Rate at Days 1, 2, 3, 4, 7, 14, 21 and 28
Heart rate was measured in terms of "beats per minute". Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. If a single time point ECG was abnormal, a triplicate ECG was required, which were obtained approximately 2-4 minutes apart; the average of the triplicate ECG measurements collected at pre-dose Day 1 served as each participant's baseline value.
Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Change From Baseline in PR Interval at Days 1, 2, 3, 4, 7, 14, 21 and 28
Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. Categorical classes for PR interval data of potential clinical concern included: max value ≥300 ms, baseline value\>200 and max increase from baseline≥25%, baseline value ≤200 and max increase from baseline ≥50%.
Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Change From Baseline in QRS Interval at Days 1, 2, 3, 4, 7, 14, 21 and 28
Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. Categorical classes for QRS interval data of potential clinical concern included: max value ≥140 ms, increase from baseline ≥50%.
Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Change From Baseline in QT Interval at Days 1, 2, 3, 4, 7, 14, 21 and 28
Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals.
Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Change From Baseline in QT Interval Corrected at Days 1, 2, 3, 4, 7, 14, 21 and 28
Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. The corrected QT interval (QTc) estimates the QT interval at a standard heart rate of 60 bpm.
Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Change From Baseline in Corrected QT Interval (Fridericia Method) (QTcF Interval) at Days 1, 2, 3, 4, 7, 14, 21 and 28
Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. QTcF = QT interval corrected using the Fridericia method. Categorical classes for QTcF data of potential clinical concern included: 450 ms≤ max value \<480 ms, 480≤ max value \<500 ms, max value ≥500 ms; 30 ms ≤ QTcF max increase from baseline \<60 ms; max increase from baseline ≥60 ms.
Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Number of Participants With Physical Examination Findings
A complete PE included assessments of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. A brief PE included assessments of the general appearance, the respiratory and cardiovascular systems, as well as participant reported symptoms. The full PE planned for Screening may have been performed on Day -1 before dosing at the discretion of the Investigator. If a full PE was done at Screening visit, a brief PE was to be conducted on Day-1. After Day -1, brief examinations based on signs and symptoms may have been performed if clinically indicated at the discretion of the Investigator to assess changes from baseline/previous visits of any ongoing symptoms.
Time frame: Screening (Day -35 to Day -2), Day -1, Day 1 (for general appearance, heart, lungs), Day 7 (for general appearance, heart, lungs), Day 28 (for general appearance, heart, lungs)
Number of Participants With Injection Site Reactions
Grades of injection site reactions were defined according to NCI CTCAE version 5.0. Grade 1=Tenderness with or without associated symptoms (eg, warmth, erythema, itching); Grade 2= Pain, lipodystrophy, edema, phlebitis; Grade 3= Ulceration or necrosis, severe tissue damage, operative intervention indicated; Grade 4=Life-threatening consequences, urgent intervention indicated; Grade 5=death. Participants with any grade of injection site reaction are reported in this outcome measure.
Time frame: Day 1 to Day 7
Mean Plasma Marstacimab Concentration Versus Time at Days 1, 2, 3, 4, 7, 14, 21 and 28
Mean plasma concentration of marstacimab after participants received a single SC injection of marstacimab 300 mg.
Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Maximum Plasma Concentration (Cmax) of Marstacimab
Maximum plasma concentration of marstacimab after participants received a single SC injection of marstacimab 300 mg.
Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Time for Cmax (Tmax) of Marstacimab
Time for Cmax of marstacimab after participants received a single SC injection of marstacimab 300 mg.
Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Marstacimab
Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration of marstacimab after participants received a single SC injection of marstacimab 300 mg.
Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinity (AUCinf) of Marstacimab
Area under the concentration time curve from time zero to infinity of marstacimab after participants received a single SC injection of marstacimab 300 mg.
Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Terminal Half-Life (t1/2) of Marstacimab
Terminal half life (t1/2) of marstacimab after participants received a single SC injection of marstacimab 300 mg. t1/2 is defined as the time for plasma concentration to decrease by one half.
Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Apparent Volume of Distribution (Vz/F) of Marstacimab
Apparent volume of distribution of marstacimab after participants received a single SC injection of marstacimab 300 mg. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was influenced by the fraction absorbed. Vz/F was calculated as dose/AUCinf. AUCinf = area under the concentration time curve from time zero to infinity.
Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Apparent Clearance (CL/F) of Marstacimab
Apparent clearance (CL/F) of marstacimab after participants received a single SC injection of marstacimab 300 mg. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as Dose/ (AUCinf\*kel). AUCinf = area under the concentration time curve from time zero to infinity. kel = terminal phase rate constant calculated by a linear regression of the log linear concentration time curve.
Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Maximum Increase From Baseline for Tissue Factor Pathway Inhibitor (TFPI), Day 1 up to Day 28
TFPI is a protease inhibitor, which acts as an antagonist of the extrinsic coagulation pathway via inhibition of tissue factor-activated coagulation factor VII (FVIIa) and activated factor X (FXa). Plasma total TFPI levels were measured to reflect target binding with marstacimab. TFPI in results represented total TFPI.
Time frame: Day 1 to Day 28
Area Under the Curve (AUC) of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TFPI
A change from baseline-time profile was established based on changes from baseline in TFPI at specific time points. Area under the TFPI change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure. TFPI represented total TFPI.
Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Maximum Increase From Baseline for Prothrombin Fragments 1+2 (PF 1+2), Day 1 up to Day 28
PF1+2 is an in vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for PF 1+2 was provided.
Time frame: Day 1 to Day 28
AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for PF 1+2
A change from baseline-time profile was established based on changes from baseline in PF 1+2 at specific time points. Area under the PF 1+2 change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.
Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Maximum Increase From Baseline for D-Dimer, Day 1 up to Day 28
D-dimer is an in vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for D-Dimer is provided.
Time frame: Day 1 to Day 28
AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for D-Dimer
A change from baseline-time profile was established based on changes from baseline in D-dimer at specific time points. Area under the D-dimer change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.
Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Maximum Decrease From Baseline for Dilute Prothrombin Time (dPT), Day 1 up to Day 28
The dilute prothrombin time (dPT) is an ex vivo endpoint reflective of coagulation pathway activation. Maximum decrease from baseline for dPT is provided.
Time frame: Day 1 to Day 28
AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for dPT
A change from baseline-time profile was established based on changes from baseline in dPT at specific time points. Area under the dPT change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.
Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Maximum Decrease From Baseline for Thrombin Generation Assay (TGA) Lag Time, Day 1 up to Day 28
TGA lag time is an ex vivo endpoint reflective of coagulation pathway activation. Maximum decrease from baseline for TGA Lag Time is provided.
Time frame: Day 1 to Day 28
AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TGA Lag Time
A change from baseline-time profile was established based on changes from baseline in TGA lag time at specific time points. Area under the TGA lag time change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.
Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Maximum Increase From Baseline for TGA Peak, Day 1 up to Day 28
TGA peak is an ex vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for TGA Peak is provided.
Time frame: Day 1 to Day 28
AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TGA Peak
A change from baseline-time profile was established based on changes from baseline in TGA peak at specific time points. Area under the TGA peak change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.
Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Maximum Increase From Baseline for TGA Endogenous Thrombin Potential (EGTP), Day 1 up to Day 28
TGA EGTP is an ex vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for TGA Endogenous Thrombin Potential is provided.
Time frame: Day 1 to Day 28
AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TGA EGTP
A change from baseline-time profile was established based on changes from baseline in TGA EGTP at specific time points. Area under the TGA EGTP change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.
Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Number of Participants With Anti-Drug Antibody (ADA) Against Marstacimab
Summary of ADA incidence by visit is presented. ADA positive was defined as titer \>=1.54.
Time frame: Day 1 pre-dose (-2 hours to -5 min prior to dosing); Day 14; Day 21; Day 28
Number of Participants With Neutralizing Antibody (NAb) Against Marstacimab
Summary of NAb incidence by visit is presented. NAb positive was defined as titer \>=1.08. ADA-positive participants (defined as titer \>=1.54) were analyzed for NAb.
Time frame: Day 1 pre-dose (-2 hours to -5 min prior to dosing); Day 14; Day 21; Day 28
| Milestone | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Started | 6 |
| Completed | 6 |
| Not completed | 0 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with study treatment. TEAEs=AEs that started during the effective duration of treatment regardless of whether a similar event existed at baseline. Grades of AEs were defined by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1=asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated;Grade 2=minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activity of daily living (ADL);Grade 3=severe or medically significant but not immediately life-threatening, hospitalization of prolongation of hospitalization indicated; disabling limiting self-care ADL;Grade 4=events with life-threatening consequences, urgent intervention indicated;Grade 5= death related to AE.Treatment-related TEAEs were determined by investigator.
| Participants | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| All-Causality TEAEs | 1 |
| Treatment-Related TEAEs | 0 |
| All-Causality Severe TEAEs | 0 |
An SAE was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect. Treatment-related SAEs were determined by the investigator.
| Participants | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with study treatment. TEAEs=AEs that started during the effective duration of treatment regardless of whether a similar event existed in the baseline period. Grades of AEs were defined by NCI CTCAE version 5.0. Grade 1=asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2=minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activity of daily living (ADL); Grade 3=severe or medically significant but not immediately life-threatening, hospitalization of prolongation of hospitalization indicated; disabling limiting self-care ADL; Grade 4=events with life-threatening consequences, urgent intervention indicated; Grade 5= death related to AE. Treatment-related TEAEs were determined by the investigator.
| Participants | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Number of Participants With Maximum Grade 3 or 4 or 5 TEAEs | 0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with study treatment. TEAEs=AEs that started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period. Grades of AEs were defined by NCI CTCAE version 5.0. Grade 1=asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2=minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activity of daily living (ADL); Grade 3=severe or medically significant but not immediately life-threatening, hospitalization of prolongation of hospitalization indicated; disabling limiting self-care ADL; Grade 4=events with life-threatening consequences, urgent intervention indicated; Grade 5= death related to AE. Treatment-related TEAEs were determined by the investigator.
| Participants | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Number of Participants With TEAEs Leading to Permanent or Temporary Discontinuation From Study | 0 |
Laboratory assessments included chemistry, hematology, Prothrombin Time/International Normalized Ratio (PT/INR), Activated Partial Thromboplastin Time (APTT), urinalysis, fibrinogen, Antithrombin III (ATIII) activity, and Cardiac Troponin I (cTnI). Laboratory test abnormalities reported by at least 1 participant are reported in this outcome measure. ULN = upper limit of normal.
| Participants | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| APTT >1.1 x ULN | 6 |
| Urine hemoglobin >=1 | 1 |
| Urobilinogen >=1 | 2 |
PT is one of the laboratory tests to evaluate the ability of blood clotting. The INR is derived from PT which is calculated as a ratio of a participant's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the World Health Organization (WHO) using the following formula: INR = Participant PT / Control PT. Blood samples were obtained to evaluate PT/INR.
| ratio | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Day 1 | 1.000 ± 0.0790 |
| Day 2 | 0.990 ± 0.0632 |
| Day 7 | 0.972 ± 0.0549 |
| Day 14 | 0.960 ± 0.0690 |
| Day 21 | 0.982 ± 0.0902 |
| Day 28 | 0.988 ± 0.0920 |
PT is one of the laboratory tests to evaluate the ability of blood clotting. The INR is derived from PT which is calculated as a ratio of a participant's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the WHO using the following formula: INR = Participant PT / Control PT. Blood samples were obtained to evaluate PT/INR.
| Ratio | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Day 2 | -0.010 ± 0.0363 |
| Day 7 | -0.028 ± 0.0611 |
| Day 14 | -0.040 ± 0.0379 |
| Day 21 | -0.018 ± 0.0492 |
| Day 28 | -0.012 ± 0.0741 |
The APTT is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood samples were obtained to evaluate APTT.
| second | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Day 1 | 85.38 ± 14.377 |
| Day 2 | 87.15 ± 15.473 |
| Day 7 | 87.78 ± 14.376 |
| Day 14 | 80.95 ± 17.521 |
| Day 21 | 64.10 ± 21.833 |
| Day 28 | 68.92 ± 16.144 |
The APTT is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood samples were obtained to evaluate APTT.
| Second | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Day 2 | 1.77 ± 6.431 |
| Day 7 | 2.40 ± 7.294 |
| Day 14 | -4.43 ± 16.987 |
| Day 21 | -21.28 ± 16.632 |
| Day 28 | -16.47 ± 13.733 |
Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.
| milligram per deciliter (mg/dL) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Day 1 | 284.3 ± 61.68 |
| Day 2 | 267.0 ± 52.37 |
| Day 7 | 249.5 ± 72.82 |
| Day 14 | 284.0 ± 50.12 |
| Day 21 | 267.7 ± 30.18 |
| Day 28 | 273.2 ± 43.73 |
Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.
| mg/dL | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Day 2 | -17.3 ± 26.82 |
| Day 7 | -34.8 ± 27.02 |
| Day 14 | -0.3 ± 39.73 |
| Day 21 | -16.7 ± 39.33 |
| Day 28 | -11.2 ± 74.66 |
ATIII is a nonvitamin K-dependent protease that inhibits coagulation by lysing thrombin and factor Xa. The antithrombin activity test measures how well the protein inhibits thrombin, with a reference range of 75% - 125%. Blood samples were obtained to evaluate ATIII activity.
| percent of antithrombin III activity | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Day 1 | 92.75 ± 6.498 |
| Day 2 | 88.68 ± 3.939 |
| Day 7 | 94.07 ± 4.384 |
| Day 14 | 97.98 ± 6.386 |
| Day 21 | 96.10 ± 3.949 |
| Day 28 | 97.18 ± 7.885 |
ATIII is a nonvitamin K-dependent protease that inhibits coagulation by lysing thrombin and factor Xa. The antithrombin activity test measures how well the protein inhibits thrombin, with a reference range of 75% - 125%. Blood samples were obtained to evaluate ATIII activity.
| percent of antithrombin III activity | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Day 2 | -4.07 ± 4.399 |
| Day 7 | 1.32 ± 5.739 |
| Day 14 | 5.23 ± 7.655 |
| Day 21 | 3.35 ± 5.899 |
| Day 28 | 4.43 ± 6.207 |
cTnI is one of the cardiac regulatory proteins that control the calcium mediated interaction between actin and myosin, and is considered a specific marker for cardiac damage. Blood samples were obtained to evaluate the amount of cTnI.
| nanogram per milliliter (ng/mL) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Day 1 | 0.0250 ± 0.00000 |
| Day 2 | 0.0250 ± 0.00000 |
| Day 4 | 0.0250 ± 0.00000 |
cTnI is one of the cardiac regulatory proteins that control the calcium mediated interaction between actin and myosin, and is considered a specific marker for cardiac damage. Blood samples were obtained to evaluate the amount of cTnI.
| ng/mL | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Day 2 | 0.0000 ± 0.0000 |
| Day 4 | 0.0000 ± 0.00000 |
Vital signs measurements included blood pressure (BP), pulse rate, respiratory rate and oral temperature. Categorical classes for vital signs of potential clinical concern included: (1) systolic BP - minimum (min) value \<90 mmHg, maximum (max) decrease/increase from baseline \>=30 mmHg; (2) diastolic BP - min value \<50 mmHg, max decrease/increase from baseline \>=20 mmHg; (3) supine pulse rate - min \<40 beat per minute (bpm) or max \>120 bpm; (4) standing pulse rate - min \<40 bpm or max \>140 bpm; (5) oral temperature \> 38.5 celsius degree (°C). BPs were measured in a supine position so standing BPs were not evaluated and not reported.
| Participants | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Supine systolic BP value <90 mmHg | 0 |
| Supine systolic BP increase from baseline >=30 mmHg | 0 |
| Supine systolic BP decrease from baseline >=30 mmHg | 0 |
| Supine diastolic BP value <50 mmHg | 0 |
| Supine diastolic BP increase from baseline >=20 mmHg | 1 |
| Supine diastolic BP decrease from baseline >=20 mmHg | 0 |
| Supine pulse rate value <40 bpm | 0 |
| Supine pulse rate value >120 bpm | 0 |
| Body temperature >38.5 °C | 0 |
BPs were assessed in a supine position with a completely automated device. Categorical classes for supine systolic BP of potential clinical concern included min value \<90 mmHg, max decrease/increase from baseline \>=30 mmHg.
| mmHg | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| 1 hour post Day 1 dosing | 2.50 ± 9.503 |
| 2 hours post Day 1 dosing | 1.67 ± 8.189 |
| 4 hours post Day 1 dosing | 4.17 ± 8.519 |
| 8 hours post Day 1 dosing | -1.83 ± 5.981 |
| 12 hours post Day 1 dosing | 3.00 ± 9.274 |
| Day 2 | -0.67 ± 6.346 |
| Day 3 | 0.17 ± 8.183 |
| Day 4 | 2.17 ± 4.446 |
| Day 7 | 1.67 ± 10.053 |
| Day 14 | 4.00 ± 7.563 |
| Day 21 | 1.00 ± 8.854 |
| Day 28 | -0.50 ± 13.019 |
BPs were assessed in a supine position with a completely automated device. Categorical classes for supine diastolic BP of potential clinical concern included min value \<50 mmHg, max decrease/increase from baseline \>=20 mmHg.
| mmHg | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| 1 hour post Day 1 dosing | -2.67 ± 7.659 |
| 2 hours post Day 1 dosing | -3.83 ± 7.910 |
| 4 hours post Day 1 dosing | -6.33 ± 7.146 |
| 8 hours post Day 1 dosing | -8.67 ± 6.653 |
| 12 hours post Day 1 dosing | -3.50 ± 8.597 |
| Day 2 | -5.17 ± 6.145 |
| Day 3 | -4.83 ± 8.085 |
| Day 4 | -5.17 ± 6.145 |
| Day 7 | -4.17 ± 9.087 |
| Day 14 | 5.83 ± 9.475 |
| Day 21 | -1.50 ± 8.118 |
| Day 28 | -0.33 ± 6.218 |
Pulse rates were assessed in a supine position with a completely automated device. Categorical classes for supine pulse rate of potential clinical concern included min value \<40 bpm or max value \>120 bpm.
| bpm | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| 1 hour post Day 1 dosing | -1.33 ± 3.011 |
| 2 hours post Day 1 dosing | -2.00 ± 3.521 |
| 4 hours post Day 1 dosing | 0.33 ± 11.003 |
| 8 hours post Day 1 dosing | -1.50 ± 11.537 |
| 12 hours post Day 1 dosing | -5.33 ± 6.501 |
| Day 2 | -6.67 ± 8.937 |
| Day 3 | -7.33 ± 6.683 |
| Day 4 | -4.33 ± 11.361 |
| Day 7 | 0.17 ± 15.198 |
| Day 14 | 14.33 ± 12.209 |
| Day 21 | 15.50 ± 13.882 |
| Day 28 | 10.50 ± 12.740 |
No eating, drinking, or smoking was allowed for 15 minutes prior to the measurement of oral temperature. The criterion for oral temperature of potential clinical concern was oral temperature \> 38.5°C.
| degree Celsius | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| 1 hour post Day 1 dosing | 0.10 ± 0.502 |
| 2 hours post Day 1 dosing | 0.28 ± 0.621 |
| 4 hours post Day 1 dosing | 0.50 ± 0.827 |
| 8 hours post Day 1 dosing | 0.17 ± 0.501 |
| 12 hours post Day 1 dosing | 0.22 ± 0.581 |
| Day 2 | 0.25 ± 0.582 |
| Day 3 | 0.10 ± 0.566 |
| Day 4 | -0.08 ± 0.523 |
| Day 7 | 0.30 ± 0.626 |
| Day 14 | 0.45 ± 0.701 |
| Day 21 | 0.67 ± 0.700 |
| Day 28 | 0.75 ± 0.579 |
Respiratory rate measurement was preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Respiratory rate was measured in terms of "breaths per minute", and was measured by observing and counting the respirations of the participant for 30 seconds and multiplied by 2.
| breaths per minute | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| 1 hour post Day 1 dosing | -0.50 ± 1.049 |
| 2 hours post Day 1 dosing | -0.67 ± 1.033 |
| 4 hours post Day 1 dosing | 0.17 ± 2.994 |
| 8 hours post Day 1 dosing | -0.50 ± 3.209 |
| 12 hours post Day 1 dosing | -1.50 ± 1.975 |
| Day 2 | -1.33 ± 1.506 |
| Day 3 | -1.67 ± 1.751 |
| Day 4 | -1.67 ± 3.502 |
| Day 7 | 1.00 ± 4.980 |
| Day 14 | 3.50 ± 2.811 |
| Day 21 | 3.83 ± 3.312 |
| Day 28 | 2.67 ± 3.141 |
Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated heart rate and measured PR, QRS and QT intervals. If a single time point ECG was abnormal, a triplicate ECG was required and obtained approximately 2-4 minutes apart; the average of triplicate ECG measurements collected at pre-dose Day 1 served as each participant's baseline value. Categorical classes for ECG data of potential clinical concern included: (1) QTcF - 450 millisecond (msec)≤ max value \<480 msec, 480 msec ≤ max value \<500 msec, max value ≥500 msec; 30 msec ≤ QTcF max increase from baseline \<60 msec; max increase from baseline ≥60 msec; (2) PR interval - max value ≥300 msec, baseline value\>200 and max increase from baseline ≥25%, baseline value ≤200 and max increase from baseline ≥50%; (3) QRS interval - max value ≥140 msec, increase from baseline ≥50%.
| Participants | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| PR Interval Value >=300 msec | 0 |
| PR Interval >=25% increase when baseline PR>200 msec, >=50% increase when baseline PR <=200 msec | 0 |
| QRS Interval value >=140 msec | 0 |
| QRS Interval % change from baseline >=50% | 0 |
| QT Interval value >500 msec | 0 |
| QTcF Interval value >= 450 msec and <480 msec | 0 |
| QTcF Interval value >= 480 msec and <500 msec | 0 |
| QTcF Interval value >= 500 msec | 0 |
| QTcF Interval change from baseline >=30 msec and <60 msec | 0 |
| QTcF Interval change from baseline >=60 msec | 0 |
Heart rate was measured in terms of "beats per minute". Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. If a single time point ECG was abnormal, a triplicate ECG was required, which were obtained approximately 2-4 minutes apart; the average of the triplicate ECG measurements collected at pre-dose Day 1 served as each participant's baseline value.
| beats per minute | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| 1 hour post Day 1 dosing | 0.43 ± 8.514 |
| 2 hours post Day 1 dosing | -1.57 ± 8.105 |
| 4 hours post Day 1 dosing | 1.43 ± 14.581 |
| 8 hours post Day 1 dosing | -1.73 ± 8.899 |
| 12 hours post Day 1 dosing | -1.57 ± 4.670 |
| Day 2 | -3.07 ± 9.917 |
| Day 3 | -3.90 ± 11.858 |
| Day 4 | -5.73 ± 10.560 |
| Day 7 | 0.60 ± 17.580 |
| Day 14 | 9.43 ± 10.869 |
| Day 21 | 3.60 ± 5.953 |
| Day 28 | 4.43 ± 10.872 |
Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. Categorical classes for PR interval data of potential clinical concern included: max value ≥300 ms, baseline value\>200 and max increase from baseline≥25%, baseline value ≤200 and max increase from baseline ≥50%.
| millisecond | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| 1 hour post Day 1 dosing | -4.22 ± 12.490 |
| 2 hours post Day 1 dosing | 0.45 ± 33.789 |
| 4 hours post Day 1 dosing | -8.38 ± 20.696 |
| 8 hours post Day 1 dosing | -6.55 ± 9.592 |
| 12 hours post Day 1 dosing | -10.88 ± 8.697 |
| Day 2 | -2.72 ± 7.236 |
| Day 3 | -6.05 ± 11.031 |
| Day 4 | -4.55 ± 8.547 |
| Day 7 | -6.22 ± 19.135 |
| Day 14 | -10.22 ± 12.921 |
| Day 21 | -8.05 ± 13.602 |
| Day 28 | -4.05 ± 23.210 |
Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. Categorical classes for QRS interval data of potential clinical concern included: max value ≥140 ms, increase from baseline ≥50%.
| millisecond | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| 1 hour post Day 1 dosing | -2.27 ± 4.698 |
| 2 hours post Day 1 dosing | -4.27 ± 6.953 |
| 4 hours post Day 1 dosing | -2.27 ± 5.972 |
| 8 hours post Day 1 dosing | -1.60 ± 4.459 |
| 12 hours post Day 1 dosing | 1.57 ± 5.315 |
| Day 2 | -2.77 ± 7.640 |
| Day 3 | -2.60 ± 5.713 |
| Day 4 | -4.10 ± 5.968 |
| Day 7 | -0.43 ± 4.855 |
| Day 14 | -5.10 ± 5.312 |
| Day 21 | -4.60 ± 5.646 |
| Day 28 | -4.60 ± 7.505 |
Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals.
| millisecond | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| 1 hour post Day 1 dosing | -6.57 ± 14.714 |
| 2 hours post Day 1 dosing | -0.90 ± 16.160 |
| 4 hours post Day 1 dosing | -11.07 ± 24.048 |
| 8 hours post Day 1 dosing | -0.07 ± 21.771 |
| 12 hours post Day 1 dosing | 2.60 ± 8.630 |
| Day 2 | 0.77 ± 20.963 |
| Day 3 | 0.60 ± 17.506 |
| Day 4 | -0.07 ± 28.348 |
| Day 7 | -5.90 ± 29.938 |
| Day 14 | -30.40 ± 21.731 |
| Day 21 | -17.57 ± 18.007 |
| Day 28 | -19.07 ± 23.601 |
Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. The corrected QT interval (QTc) estimates the QT interval at a standard heart rate of 60 bpm.
| millisecond | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| 1 hour post Day 1 dosing | -4.15 ± 14.416 |
| 2 hours post Day 1 dosing | -4.82 ± 11.811 |
| 4 hours post Day 1 dosing | -7.15 ± 22.601 |
| 8 hours post Day 1 dosing | -4.15 ± 11.556 |
| 12 hours post Day 1 dosing | -0.32 ± 11.397 |
| Day 2 | -7.82 ± 16.104 |
| Day 3 | -11.65 ± 17.928 |
| Day 4 | -16.82 ± 8.169 |
| Day 7 | -4.98 ± 22.013 |
| Day 14 | -8.48 ± 15.359 |
| Day 21 | -8.98 ± 12.716 |
| Day 28 | -8.65 ± 11.854 |
Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. QTcF = QT interval corrected using the Fridericia method. Categorical classes for QTcF data of potential clinical concern included: 450 ms≤ max value \<480 ms, 480≤ max value \<500 ms, max value ≥500 ms; 30 ms ≤ QTcF max increase from baseline \<60 ms; max increase from baseline ≥60 ms.
| millisecond | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| 1 hour post Day 1 dosing | -5.38 ± 8.692 |
| 2 hours post Day 1 dosing | -3.22 ± 7.499 |
| 4 hours post Day 1 dosing | -8.55 ± 12.561 |
| 8 hours post Day 1 dosing | -2.88 ± 10.471 |
| 12 hours post Day 1 dosing | 0.28 ± 8.084 |
| Day 2 | -4.88 ± 12.496 |
| Day 3 | -7.05 ± 7.900 |
| Day 4 | -10.88 ± 11.337 |
| Day 7 | -5.55 ± 9.932 |
| Day 14 | -15.22 ± 11.354 |
| Day 21 | -11.05 ± 12.049 |
| Day 28 | -11.38 ± 9.550 |
A complete PE included assessments of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. A brief PE included assessments of the general appearance, the respiratory and cardiovascular systems, as well as participant reported symptoms. The full PE planned for Screening may have been performed on Day -1 before dosing at the discretion of the Investigator. If a full PE was done at Screening visit, a brief PE was to be conducted on Day-1. After Day -1, brief examinations based on signs and symptoms may have been performed if clinically indicated at the discretion of the Investigator to assess changes from baseline/previous visits of any ongoing symptoms.
| Participants | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Ears at screening | 0 |
| Ears on Day -1 | 0 |
| Eyes at screening | 0 |
| Eyes on Day -1 | 0 |
| Gastrointestinal at screening | 0 |
| Gastrointestinal on Day -1 | 0 |
| General appearance at screening | 0 |
| General appearance on Day -1 | 0 |
| General appearance on Day 1 | 0 |
| General appearance on Day 7 | 0 |
| General appearance on Day 28 | 0 |
| Head at screening | 0 |
| Head on Day -1 | 0 |
| Heart at screening | 0 |
| Heart on Day -1 | 0 |
| Heart on Day 1 | 0 |
| Heart on Day 7 | 0 |
| Heart on Day 28 | 0 |
| Lungs at screening | 0 |
| Lungs on Day -1 | 0 |
| Lungs on Day 1 | 0 |
| Lungs on Day 7 | 0 |
| Lungs on Day 28 | 0 |
| Lymph nodes at screening | 0 |
| Lymph nodes on Day -1 | 0 |
| Mouth at screening | 0 |
| Mouth on Day -1 | 0 |
| Musculoskeletal system at screening | 6 |
| Musculoskeletal system on Day -1 | 6 |
| Neurological system at screening | 0 |
| Neurological system on Day -1 | 0 |
| Nose at screening | 0 |
| Nose on Day -1 | 0 |
| Skin at screening | 0 |
| Skin on Day -1 | 0 |
Grades of injection site reactions were defined according to NCI CTCAE version 5.0. Grade 1=Tenderness with or without associated symptoms (eg, warmth, erythema, itching); Grade 2= Pain, lipodystrophy, edema, phlebitis; Grade 3= Ulceration or necrosis, severe tissue damage, operative intervention indicated; Grade 4=Life-threatening consequences, urgent intervention indicated; Grade 5=death. Participants with any grade of injection site reaction are reported in this outcome measure.
| Participants | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Number of Participants With Injection Site Reactions | 0 |
Mean plasma concentration of marstacimab after participants received a single SC injection of marstacimab 300 mg.
| ng/mL | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Day 1 pre-dose | 0.0000 ± 0.0000 |
| 1 hour post Day 1 dosing | 582.0 ± 1313.2 |
| 4 hours post Day 1 dosing | 1746 ± 960.3 |
| 12 hours post Day 1 dosing | 5647 ± 2254.2 |
| Day 2, 24 hours post Day 1 dosing | 9033 ± 3349.8 |
| Day 3, 48 hours post Day 1 dosing | 14300 ± 5510.3 |
| Day 4, 72 hours post Day 1 dosing | 16060 ± 5706.9 |
| Day 7, approximately 144 hours post Day 1 dosing | 14600 ± 4693.9 |
| Day 14, approximately 312 hours post Day 1 dosing | 3437 ± 2349.3 |
| Day 21, approximately 480 hours post Day 1 dosing | 53.17 ± 130.23 |
| Day 28, approximately 648 hours post Day 1 dosing | 0.0000 ± 0.0000 |
Maximum plasma concentration of marstacimab after participants received a single SC injection of marstacimab 300 mg.
| ng/mL | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Maximum Plasma Concentration (Cmax) of Marstacimab | 15610 ± 35 |
Time for Cmax of marstacimab after participants received a single SC injection of marstacimab 300 mg.
| hour | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Time for Cmax (Tmax) of Marstacimab | 73.15 (71.9 to 167) |
Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration of marstacimab after participants received a single SC injection of marstacimab 300 mg.
| nanogram * hour/milliliter (ng*hr/mL) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Marstacimab | 2917000 ± 60 |
Area under the concentration time curve from time zero to infinity of marstacimab after participants received a single SC injection of marstacimab 300 mg.
| ng*hr/mL | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinity (AUCinf) of Marstacimab | 4549000 ± 7 |
Terminal half life (t1/2) of marstacimab after participants received a single SC injection of marstacimab 300 mg. t1/2 is defined as the time for plasma concentration to decrease by one half.
| hour | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Terminal Half-Life (t1/2) of Marstacimab | 90.48 ± 26.025 |
Apparent volume of distribution of marstacimab after participants received a single SC injection of marstacimab 300 mg. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was influenced by the fraction absorbed. Vz/F was calculated as dose/AUCinf. AUCinf = area under the concentration time curve from time zero to infinity.
| Liter | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Apparent Volume of Distribution (Vz/F) of Marstacimab | 8.305 ± 29 |
Apparent clearance (CL/F) of marstacimab after participants received a single SC injection of marstacimab 300 mg. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as Dose/ (AUCinf\*kel). AUCinf = area under the concentration time curve from time zero to infinity. kel = terminal phase rate constant calculated by a linear regression of the log linear concentration time curve.
| Liter per hour | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Apparent Clearance (CL/F) of Marstacimab | 0.06595 ± 7 |
TFPI is a protease inhibitor, which acts as an antagonist of the extrinsic coagulation pathway via inhibition of tissue factor-activated coagulation factor VII (FVIIa) and activated factor X (FXa). Plasma total TFPI levels were measured to reflect target binding with marstacimab. TFPI in results represented total TFPI.
| ng/mL | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Maximum Increase From Baseline for Tissue Factor Pathway Inhibitor (TFPI), Day 1 up to Day 28 | 79.50 ± 36.374 |
A change from baseline-time profile was established based on changes from baseline in TFPI at specific time points. Area under the TFPI change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure. TFPI represented total TFPI.
| ng*hr/mL | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| AUC of change from baseline values Days 1-7 for TFPI | 5730.07 ± 2891.283 |
| AUC of change from baseline values Days 1-14 for TFPI | 15425.73 ± 9469.364 |
| AUC of change from baseline values Days 1-28 for TFPI | 15526.33 ± 14100.382 |
PF1+2 is an in vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for PF 1+2 was provided.
| picomole per liter (pmol/L) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Maximum Increase From Baseline for Prothrombin Fragments 1+2 (PF 1+2), Day 1 up to Day 28 | 531.9 ± 126.91 |
A change from baseline-time profile was established based on changes from baseline in PF 1+2 at specific time points. Area under the PF 1+2 change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.
| picomole * hour/liter (pmol*hr/L) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| AUC of change from baseline values Days 1-7 for PF 1+2 | 56871.2823 ± 17578.69955 |
| AUC of change from baseline values Days 1-14 for PF 1+2 | 116439.2948 ± 38634.76646 |
| AUC of change from baseline values Days 1-28 for PF 1+2 | 144733.7020 ± 49783.67150 |
D-dimer is an in vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for D-Dimer is provided.
| microgram per milliliter (µg/mL) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Maximum Increase From Baseline for D-Dimer, Day 1 up to Day 28 | 0.463 ± 0.2881 |
A change from baseline-time profile was established based on changes from baseline in D-dimer at specific time points. Area under the D-dimer change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.
| microgram * hour/milliliter (µg*hr/mL) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| AUC of change from baseline values Days 1-7 for D-dimer | 46.245 ± 29.3806 |
| AUC of change from baseline values Days 1-14 for D-dimer | 110.855 ± 71.0567 |
| AUC of change from baseline values Days 1-28 for D-dimer | 176.463 ± 153.1565 |
The dilute prothrombin time (dPT) is an ex vivo endpoint reflective of coagulation pathway activation. Maximum decrease from baseline for dPT is provided.
| second | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Maximum Decrease From Baseline for Dilute Prothrombin Time (dPT), Day 1 up to Day 28 | -19.62 ± 13.079 |
A change from baseline-time profile was established based on changes from baseline in dPT at specific time points. Area under the dPT change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.
| second * hour (sec*hr) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| AUC of change from baseline values Days 1-7 for dPT | -1910.10 ± 1800.853 |
| AUC of change from baseline values Days 1-14 for dPT | -4079.87 ± 4094.644 |
| AUC of change from baseline values Days 1-28 for dPT | -6792.18 ± 7068.384 |
TGA lag time is an ex vivo endpoint reflective of coagulation pathway activation. Maximum decrease from baseline for TGA Lag Time is provided.
| minute | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Maximum Decrease From Baseline for Thrombin Generation Assay (TGA) Lag Time, Day 1 up to Day 28 | -0.92 ± 0.279 |
A change from baseline-time profile was established based on changes from baseline in TGA lag time at specific time points. Area under the TGA lag time change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.
| minute * hour (min*hr) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| AUC of change from baseline values Days 1-7 for TGA lag time | -95.10 ± 37.787 |
| AUC of change from baseline values Days 1-14 for TGA lag time | -188.08 ± 81.227 |
| AUC of change from baseline values Days 1-28 for TGA lag time | -174.70 ± 234.641 |
TGA peak is an ex vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for TGA Peak is provided.
| nanomole (nmol) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Maximum Increase From Baseline for TGA Peak, Day 1 up to Day 28 | 105.83 ± 13.124 |
A change from baseline-time profile was established based on changes from baseline in TGA peak at specific time points. Area under the TGA peak change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.
| nanomole * hour (nmol*hr) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| AUC of change from baseline values Days 1-7 for TGA peak | 10584.58 ± 3169.434 |
| AUC of change from baseline values Days 1-14 for TGA peak | 20276.98 ± 5557.219 |
| AUC of change from baseline values Days 1-28 for TGA peak | 28016.08 ± 9062.199 |
TGA EGTP is an ex vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for TGA Endogenous Thrombin Potential is provided.
| nanomole * minute (nmol*min) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Maximum Increase From Baseline for TGA Endogenous Thrombin Potential (EGTP), Day 1 up to Day 28 | 1093.7 ± 332.76 |
A change from baseline-time profile was established based on changes from baseline in TGA EGTP at specific time points. Area under the TGA EGTP change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.
| nanomole * minute * hour (nmol*min*hr) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| AUC of change from baseline values Days 1-7 for TGA EGTP | 123700.0 ± 35312.50 |
| AUC of change from baseline values Days 1-14 for TGA EGTP | 238797.8 ± 47387.58 |
| AUC of change from baseline values Days 1-28 for TGA EGTP | 332461.2 ± 69573.95 |
Summary of ADA incidence by visit is presented. ADA positive was defined as titer \>=1.54.
| Participants | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Day 1 | 0 |
| Day 14 | 0 |
| Day 21 | 1 |
| Day 28 | 1 |
Summary of NAb incidence by visit is presented. NAb positive was defined as titer \>=1.08. ADA-positive participants (defined as titer \>=1.54) were analyzed for NAb.
| Participants | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Day 1 | 0 |
| Day 14 | 0 |
| Day 21 | 0 |
| Day 28 | 0 |
Collected over Baseline (Day 1) to Day 42. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Event | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/6 |
Baseline analysis population included all participants enrolled in the study who received the study intervention.
| Age, Continuous(years) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Median | 31.5 (27 to 34) |
| Age, Customized(Participants) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| <18 years | 0 |
| 18-64 years | 6 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Female | 0 |
| Male | 6 |
| Ethnicity (NIH/OMB)(Participants) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| Chinese | 6 |
| Other (Not Chinese) | 0 |
| Race/Ethnicity, Customized(Participants) | PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose |
|---|---|
| White | 0 |
| Black or African American | 0 |
| Asian | 6 |
| American Indian or Alaska Native | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Apr 2021 to primary completion in Aug 2021, 3 months.
Results were first posted in Jul 2023, 1 year 10 months after primary completion.
Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 3 months is below that.
Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Marstacimab